Sagimet Biosciences (SGMT) Share-based Compensation (2022 - 2026)

Sagimet Biosciences' Share-based Compensation history spans 5 years, with the latest figure at $1.8 million for Q1 2026.

  • Quarterly Share-based Compensation rose 24.93% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Mar 2026, up 13.58% year-over-year, with the annual reading at $6.4 million for FY2025, 21.96% up from the prior year.
  • Share-based Compensation came in at $1.8 million for Q1 2026, up from $1.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q3 2023 to a low of $383000.0 in Q2 2022.
  • The 5-year median for Share-based Compensation is $1.5 million (2024), against an average of $1.3 million.
  • Year-over-year, Share-based Compensation soared 376.86% in 2023 and then decreased 16.66% in 2024.
  • Sagimet Biosciences' Share-based Compensation stood at $721000.0 in 2022, then skyrocketed by 81.83% to $1.3 million in 2023, then rose by 17.01% to $1.5 million in 2024, then increased by 10.23% to $1.7 million in 2025, then rose by 8.75% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Share-based Compensation are $1.8 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025).